Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has scheduled its 24th Annual General Meeting to be held on 27th August 2026.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced an analyst/institutional investor meeting, Emkay Confluence 2026, scheduled for August 12, 2026, in Mumbai, India. The meeting is subject to change due to exigencies, and no unpublished price-sensitive information will be shared.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has published unaudited financial results for the 1st quarter ended June 30, 2026, in the Financial Express and Navatelangana newspapers, as per Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has made available the audio recording of its conference call with investors and analysts for Q1 FY27 on its website.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, related to the QIP issue of ₹1,500 crore. The report, issued by CARE Ratings Limited, has been reviewed by the Audit Committee of the Company and is enclosed with the announcement.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has filed a statement of deviation for the quarter ended June 30, 2026, stating that there was no deviation in the utilization of funds raised through a Qualified Institutional Placement.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced its unaudited financial results for Q1FY27, showing a 36.1% growth in total revenue and a 20.1% growth in EBITDA. The company's consolidated EPS for the period ended 30th June 2026 is INR 1.04, a degrowth of 47.2% on YoY basis.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has released an investor presentation for unaudited Q1 FY2026 financial results, as per Regulation 30 of SEBI (LODR) Regulations, 2015.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced its Q1 2026-27 financial results, with the Board of Directors approving the unaudited standalone and consolidated financial results. The company has also approved a loan of up to ₹650 crores to subsidiaries or associates, and a loan of up to ₹25 crores to a material subsidiary. The financial results are available on the company's website and on the websites of BSE and NSE.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has announced the outcome of its Board meeting held on 03rd August 2026. The Board approved the unaudited standalone financial results for the 01st quarter ended 30th June 2026, along with the Limited Review Reports. Additionally, the Board approved loan facilities of up to ₹650 Crores to subsidiaries or associates, and a loan of up to ₹25 Crores to a material subsidiary. The financial results are available on the company's website and will be published in newspapers as per SEBI regulations.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd. will host a conference call with analysts and investors on August 4, 2026, to discuss its business strategy and outlook post Q1FY27 financial results.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 03/08/2026 to consider and approve the unaudited financial results for the 1st quarter ended June 30, 2026.

Krishna Institute of Medical Sciences Ltd

Krishna Institute of Medical Sciences Ltd has received approval from both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) for the listing of 1,98,67,549 new equity shares. These shares, each with a face value of Rs. 2/-, were issued to qualified institutional buyers through a qualified institutional placement (QIP). This intimation confirms the final procedural step for the shares to be traded on the exchanges following the successful completion of the QIP.